Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy

EP: 1.The Evolution of ALK+ NSCLC Care

EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond

EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3

EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC

EP: 5.Key Differences Among ALK Inhibitors

EP: 6.Navigating ALK Inhibitor Toxicities

EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs

EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors

EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization

EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC

EP: 11.Education and Support After Progression ALK Inhibitors

Now Viewing

EP: 12.Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy

Future Directions

• Key Discussion Points:
• Dr Lovly highlighted promising clinical trials that may reshape ALK+ NSCLC treatment sequencing strategies

Notable Expert Insights

• Dr Dietrich provided critical analysis of the CROWN trial data and the implications of matching-adjusted indirect comparisons between different ALK inhibitors for clinical decision-making
• Dr Lovly offered specialized perspective on resistance patterns and mutation-guided therapy selection, particularly incorporating emerging data on investigational agents like NVL-655
• Elizabeth Castronovo contributed valuable real-world experience comparing clinical trial outcomes with observed patient responses and toxicity management approaches
• Mary Grizzard emphasized patient-centered care considerations, highlighting education strategies and practical challenges faced during treatment transitions

The panelists collectively addressed the evolving treatment landscape for ALK+ NSCLC, emphasizing evidence-based approaches to optimize patient outcomes through appropriate therapy selection, sequencing strategies, and adverse event management.